306296-73-1

Upstream product

• 24424-99-5 di-tert-butyl dicarbonate 
• 14818-53-2 N-(3,5-dimethylphenyl)-2,2,2-trifluoroacetamide 
• 306297-11-0 N-(4-bromo-3,5-dimethylphenyl)-2,2,2-trifluoro-acetamide 
• 108-69-0 3,5-dimethylaminoaniline 
• 306297-12-1 N₁-[4-(tert-butoxy)carbonyl-3,5-dimethylphenyl]-2,2,2-trifluoroacetamide 

Downstream Products

• 16752-16-2 4-amino-2,6-dimethyl benzoic acid 
• 306297-22-3 C₁₄H₂₁NO₂ 
• 1357101-73-5 N₂-(4-carboxy-3,5-dimethyl)phenyl-5-methyl-N₄-(2-oxo-2,3-dihydro-1,3-benzoxazol-5-yl)-2,4-pyrimidinediamine 
• 1357101-75-7 N₂-(3,5-dimethyl-4-hydroxymethyl)phenyl-5-methyl-N₄-(2-oxo-2,3-dihydro-1,3-benzoxazol-5-yl)-2,4-pyrimidinediamine 
• 1357101-76-8 N₂-(3,5-dimethyl-4-methoxymethyl)phenyl-5-methyl-N₄-(2-oxo-2,3-dihydro-1,3-benzoxazol-5-yl)-2,4-pyrimidinediamine 
• 1357101-83-7 N₂-(4-tert-butoxycarbonyl-3,5-dimethyl)phenyl-5-methyl-N₄-(2-oxo-2,3-dihydro-1,3-benzoxazol-5-yl)-2,4-pyrimidinediamine 

Relevant academic research and scientific papers

COMPOSITIONS AND METHODS FOR INHIBITION OF THE JAK PATHWAY

Disclosed are compounds of formula I, compositions containing them, and methods of use for the compounds and compositions in the treatment of conditions in which modulation of the JAK pathway or inhibition of JAK kinases, particularly JAK 2 and JAK3, are

CHEMOKINE RECEPTOR BINDING COMPOUNDS

The present invention relates to chemokine receptor binding compounds, pharmaceutical compositions and their use. More specifically, the present invention relates to modulators of chemokine receptor activity, preferably modulators of CCR5. Thesd compounds demonstrate protective effects against infection of target cells by a human immunodeficiency virus (HIV).

PIPERAZINE DERIVATIVES USEFUL AS CCR5 ANTAGONISTS

The use is described of CCR5 antagonists of formula (I) or a pharmaceutically acceptable salt thereof, wherein: R is optionally substituted phenyl, pyridyl, thiophenyl or naphthyl; R 1 is hydrogen or alkyl; R 2 is substituted phenyl, substituted heteroary

Piperazine derivatives useful as CCR5 antagonists

The use of CCR5 antagonists of the formula or a pharmaceutically acceptable salt thereof, wherein R is optionally substituted phenyl, pyridyl, thiophenyl or naphthyl; R1is hydrogen or alkyl; R2is substituted phenyl, substituted heter